Restricted accessResearch articleFirst published online 2009-10
Management of Metastatic Bone Pain with Repeated Doses of Rhenium 186-HEDP in Patients Under Therapy with Zoledronic Acid: A Safe and Additively Effective Practice
The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with 186Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer.
Materials and Methods:
Forty-five (45) patients received multiple therapies of 186Re-HEDP (n = 77), under a stable regimen of analgesics and zoledronic acid, far off other therapeutic manipulations, and with no extraosseous disease progression. Hematologic status and pain indices were followed up regularly.
Results:
Evaluable patients (n = 12), received 31 186Re-HEDP therapies. After the first treatment with 186Re-HEDP, the mean percentile decrease for hemoglobin was 4.7%, for white blood cells was 21.4%, and for platelets was 12%. After multiple therapies, the respective declines were 7.0%, 16.0%, and 23.4%. With respect to baseline blood counts, only thrombocytes showed a tendency for greater decrease after repeated treatments, yet not of clinical significance. Favorable clinical response occurred after the first therapy in 10 of 12 patients (83.3%), after multiple doses in 15 of 19 (78.9%), and overall in 25 of 31 (80.6%) of 186Re-HEDP therapies. Significant post-therapy improvement in pain indices was observed in all cases, regardless of the number of therapeutic doses.
Conclusions:
Retreatments with 186Re-HEDP under zoledronic acid provide continuing effectiveness in metastatic bone pain and are safe enough, if an acceptable baseline hematologic status exists.
Get full access to this article
View all access options for this article.
References
1.
MaxonHR, SchroderLE, ThomasSRet al.Rhenium-186(Sn) HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology, 1990; 176:155.
2.
MaxonHR, SchroderLE, HertzbergVSet al.Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med, 1991; 32:1877.
3.
GrahamMC, ScherHI, LiuGBet al.Rhenium-186-labeled hydroxyethylene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res, 1999; 5:1307.
4.
LamMGEH, de KlerkJMH, van RijkPP. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging, 2004; 31:S162.
5.
de KlerkJMH, ZonnenbergBA, van het SchipADet al.Dose escalation study of Re-186 HEDP in patients with metastatic prostate cancer. Eur J Nucl Med, 1994; 21:1113.
6.
LewingtonVJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med, 1993; 20:66.
7.
SciutoR, TofaniA, FestaAet al.Short- and long-term effects of 186Re-1,-1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med, 2000; 41:647.
8.
DafermouA, ColamussiP, GigantiMet al.A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med, 2001; 28:788.
9.
LewingtonVJ. Bone-seeking radionuclides for therapy. J Nucl Med, 2005; 46:38S.
10.
LeondiA, ValotassiouV, LeontopoulouSet al.Effect of combined biphosphonates and 186Re-HEDP in women with breast cancer and disseminated bone metastases [abstract]Turk J Nucl Med, 2004; 13:69.
11.
LiangJG, JiangNY, DUJQet al.Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis. Zhonghua Zhong Liu Za Zhi, 2005; 27:180.
12.
StortoG, KlainM, PaoneGet al.Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone, 2006; 39:35.
13.
WangRF, ZhangCL, ZhuSLet al.Comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract, 2003; 12:97.
14.
LamMG, DahmaneA, StevensWHet al.Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging, 2008; 35:756.
15.
BodeiL, LamM, ChiesaCet al.EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging, 2008; 35:1934.
16.
TongD, GillickL, HendricksonFR. The palliation of symptomatic osseous metastases. Final results of the study by the radiation therapy oncology group. Cancer, 1982; 50:893.
17.
FangN, LiY, XuYSet al.Serum concentrations of IL-2 and TNF-α in patients with painful bone metastases: Correlation with responses to 89SrCl2 therapy. J Nucl Med, 2006; 47:242.
18.
PonsF, HerranzR, GarciaAet al.Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med, 1997; 24:1210.
19.
KarnofskyDA, AbelmannWH, CraverLFet al.The use of nitrogen mustards in the palliative treatment of cancer. Cancer, 1948; 1:634.
20.
SolowayMS, HardemanSW, HickeyDet al.Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 1988; 61:195.
21.
World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication 48: Geneva: Switzerland: World Health Organization, 1979.
22.
SiegelS, CastellanJJr.Nonparametric Statistics for the Behavioural Sciences, 2nd. New York: McGraw Hill, 1988.
23.
DudewiczEJ, MishraSN. Modern Mathematical Statistics. New York: Wiley, 1988.
24.
MatthewsDE, FarewellVT. Using and understanding medical statistics. Basel, Switzerland: Karger, 1996.
25.
MotulskyH. Intuitive Biostatistics. New York: Oxford University, 1995.
26.
QuiltyPM, KirkD, BolgerJJet al.A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol, 1994; 31:33.
27.
MaxonHR, ThomasSR, HertzbergVSet al.Rhenium-186-hydroxyethylidene diphosphonate for the treatment of painful bone metastases. Semin Nucl Med, 1992; 22:33.
28.
Kolesnikov-GauthierH, CarpentierP, DepreuxPet al.Evaluation of toxicity and efficacy of Re-186-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med, 2000; 41:1689.
29.
SciutoR, FestaA, PasqualoniRet al.Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat, 2001; 66:101.
30.
LaingAH, AckeryDM, BaylyRJet al.Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol, 1991; 64:816.
31.
CrawfordED, KozlowskiJM, DebruyneFMJet al.The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology, 1994; 44:481.
32.
SilbersteinEB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med, 2005; 35:152.
33.
ZonnenbergBA, de KlerkJMH, van RijkPPet al.Re-186 HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer: Preliminary results. J Nucl Med, 1999; 40:639.
34.
McEwanAJ. Unsealed source therapy of painful bone metastases: An update. Semin Nucl Med, 1997; 27:165.
35.
SilbersteinEB. Advances in our understanding of the treatment of painful bone metastases. J Nucl Med, 2000; 41:655.
36.
FusterD, HerranzR, AlcoverJet al.Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm. Rev Exp Nucl Med, 2000; 19:270.
37.
KasalickyJ, KrajskaV. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med, 1998; 25:1362.
38.
TurnerJH, ClaringboldPG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphate. Eur J Cancer, 1991; 27:1084.
39.
PaszkowskiAL, HewittDJ, TaylorAJr.Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med, 1999; 24:852.
40.
HillegondsDJ, FranklinS, SheltonDKet al.The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc, 2007; 99:785.
